43 related articles for article (PubMed ID: 37506342)
1. Nanoadjuvants Produced by Advanced Nanochelating Technology in the Inactivated-Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine Formulation: Preliminary Results on Cytokines and IgG Responses.
Kalanaky S; Fakharzadeh S; Karimi P; Hafizi M; Jamaati H; Hassanzadeh SM; Khorasani A; Mahdavi M; Nazaran MH
Viral Immunol; 2023; 36(6):409-423. PubMed ID: 37506342
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus.
Dillard JA; Taft-Benz SA; Knight AC; Anderson EJ; Pressey KD; Parotti B; Martinez SA; Diaz JL; Sarkar S; Madden EA; De la Cruz G; Adams LE; Dinnon KH; Leist SR; Martinez DR; Schäfer A; Powers JM; Yount BL; Castillo IN; Morales NL; Burdick J; Evangelista MKD; Ralph LM; Pankow NC; Linnertz CL; Lakshmanane P; Montgomery SA; Ferris MT; Baric RS; Baxter VK; Heise MT
Nat Commun; 2024 May; 15(1):3738. PubMed ID: 38702297
[TBL] [Abstract][Full Text] [Related]
3. The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.
Xu K; Li J; Lu X; Ge X; Wang K; Wang J; Qiao Z; Quan Y; Li C
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250873
[TBL] [Abstract][Full Text] [Related]
4. Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates.
Siriwattananon K; Manopwisedjaroen S; Shanmugaraj B; Rattanapisit K; Phumiamorn S; Sapsutthipas S; Trisiriwanich S; Prompetchara E; Ketloy C; Buranapraditkun S; Wijagkanalan W; Tharakhet K; Kaewpang P; Leetanasaksakul K; Kemthong T; Suttisan N; Malaivijitnond S; Ruxrungtham K; Thitithanyanont A; Phoolcharoen W
Front Plant Sci; 2021; 12():682953. PubMed ID: 34054909
[TBL] [Abstract][Full Text] [Related]
5. Self-Assembling Sulfated
Zhang S; Fan W; Ding C; Zhang M; Liu S; Liu W; Tang Z; Huang C; Yan L; Song S
ACS Appl Mater Interfaces; 2024 Apr; 16(15):18591-18607. PubMed ID: 38564431
[TBL] [Abstract][Full Text] [Related]
6. MIL-53(Al)-oil/water emulsion composite as an adjuvant promotes immune responses to an inactivated pseudorabies virus vaccine in mice and pigs.
Yang B; Nie J; Guo A; Xie N; Cui Y; Sun W; Li Y; Li X; Wu Y; Liu Y
Acta Biomater; 2024 Jun; ():. PubMed ID: 38838909
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant-dependent effects on the safety and efficacy of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus.
Heise M; Dillard J; Taft-Benz S; Knight A; Anderson E; Pressey K; Parotti B; Martinez S; Diaz J; Sarkar S; Madden E; De la Cruz G; Adams L; Dinnon K; Leist S; Martinez D; Schaefer A; Powers J; Yount B; Castillo I; Morales N; Burdick J; Evangelista MK; Ralph L; Pankow N; Linnertz C; Lakshmanane P; Montgomery S; Ferris M; Baric R; Baxter V
Res Sq; 2023 Oct; ():. PubMed ID: 37961507
[TBL] [Abstract][Full Text] [Related]
8. Adjuvants for Coronavirus Vaccines.
Liang Z; Zhu H; Wang X; Jing B; Li Z; Xia X; Sun H; Yang Y; Zhang W; Shi L; Zeng H; Sun B
Front Immunol; 2020; 11():589833. PubMed ID: 33240278
[TBL] [Abstract][Full Text] [Related]
9. Review: Unravelling the Role of DNA Sensing in Alum Adjuvant Activity.
Gatt Z; Gunes U; Raponi A; da Rosa LC; Brewer JM
Discov Immunol; 2023; 2(1):kyac012. PubMed ID: 38567066
[TBL] [Abstract][Full Text] [Related]
10. Structural characterization and adjuvant activity of a water soluble polysaccharide from Poria cocos.
Gu P; Xu P; Zhu Y; Zhao Q; Zhao X; Fan Y; Wang X; Ma N; Bao Y; Shi W
Int J Biol Macromol; 2024 Jun; 273(Pt 1):133067. PubMed ID: 38866287
[TBL] [Abstract][Full Text] [Related]
11. Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen.
Doss-Gollin S; Thomas S; Brook B; Abedi K; Lebas C; Auderset F; Lugo-Rodriguez Y; Sanchez-Schmitz G; Dowling DJ; Levy O; van Haren SD
NPJ Vaccines; 2023 Oct; 8(1):163. PubMed ID: 37884538
[TBL] [Abstract][Full Text] [Related]
12. Immune Potentiation of PLGA Controlled-Release Vaccines for Improved Immunological Outcomes.
Cassaidy BJ; Moser BA; Solanki A; Chen Q; Shen J; Gotsis K; Lockhart Z; Rutledge N; Rosenberger MG; Dong Y; Davis D; Esser-Kahn AP
ACS Omega; 2024 Mar; 9(10):11608-11614. PubMed ID: 38496947
[TBL] [Abstract][Full Text] [Related]
13. Assessment of In Vitro Immunostimulatory Activity of an Adjuvanted Whole-Cell Inactivated
Bagwe P; Bajaj L; Gala RP; D'Souza MJ; Zughaier SM
Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891147
[TBL] [Abstract][Full Text] [Related]
14. Supramolecular Nanostructures for Vaccines.
Carmona-Ribeiro AM
Biomimetics (Basel); 2021 Dec; 7(1):. PubMed ID: 35076466
[TBL] [Abstract][Full Text] [Related]
15. Inactivated vaccine fueled adaptive immune responses to Omicron in 2-year COVID-19 convalescents.
Liu M; Zhang J; Li L; Tian J; Yang M; Shang B; Wang X; Li M; Li H; Yue C; Yao S; Lin Y; Guo Y; Zong K; Zhang D; Zhao Y; Cai K; Dong S; Xu S; Zhan J; Gao GF; Liu WJ
J Med Virol; 2023 Aug; 95(8):e28998. PubMed ID: 37548149
[TBL] [Abstract][Full Text] [Related]
16. Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination.
Harthaller T; Falkensammer B; Bante D; Huber M; Schmitt M; Benainouna H; Rössler A; Fleischer V; von Laer D; Kimpel J; Würzner R; Borena W
Front Immunol; 2023; 14():1196988. PubMed ID: 37545492
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 antibody response in SARS survivors with and without the COVID-19 vaccine.
Xia CS; Zhan M; Liu Y; Yue ZH; Song Y; Zhang F; Wang H
Int J Antimicrob Agents; 2023 Oct; 62(4):106947. PubMed ID: 37544384
[TBL] [Abstract][Full Text] [Related]
18. A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross-Protection Activity against Multiple SARS-CoV-2 Sublineages.
Zhang X; Wu S; Liu J; Chen R; Zhang Y; Lin Y; Xi Z; Deng J; Pu Z; Liang C; Feng J; Li R; Lin K; Zhou M; Liu Y; Zhang X; Liu B; Zhang Y; He X; Zhang H
Adv Sci (Weinh); 2023 Sep; 10(27):e2301034. PubMed ID: 37526323
[TBL] [Abstract][Full Text] [Related]
19. Review of concerned SARS-CoV-2 variants like Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (B.1.1.529), as well as novel methods for reducing and inactivating SARS-CoV-2 mutants in wastewater treatment facilities.
Zahmatkesh S; Sillanpaa M; Rezakhani Y; Wang C
J Hazard Mater Adv; 2022 Aug; 7():100140. PubMed ID: 37520798
[TBL] [Abstract][Full Text] [Related]
20. BNT162b2 or CoronaVac as the Third Dose against Omicron: Neutralizing Antibody Responses among Transplant Recipients Who Had Received Two Doses of CoronaVac.
Erol Ç; Kuloğlu ZE; Kayaaslan B; Esken G; Altunsoy A; Barlas T; Çınar G; Hasanoğlu İ; Oruç E; İncir S; Azap A; Korkmaz G; Turan Gökçe D; Kırımker OE; Coşkun Yenigün E; Ölçücüoğlu E; Ayvazoğlu Soy E; Çetinkünar S; Kurt Azap Ö; Can F; Haberal M
Viruses; 2023 Jul; 15(7):. PubMed ID: 37515220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
